TY - JOUR
T1 - Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients
AU - Alloway, Rita
AU - Steinberg, Steven
AU - Khalil, Kassem
AU - Gourishankar, Sita
AU - Miller, Joshua
AU - Norman, Douglas
AU - Hariharan, Sundaram
AU - Pirsch, John
AU - Matas, Arthur
AU - Zaltzman, Jeffrey
AU - Wisemandle, Kathleen
AU - Fitzsimmons, William
AU - First, M. Roy
PY - 2007/6
Y1 - 2007/6
N2 - Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.
AB - Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.
KW - Conversion
KW - Extended-release
KW - Kidney transplant recipients
KW - Tacrolimus twice-a-day
KW - Two-year safety
KW - XL once-daily
UR - http://www.scopus.com/inward/record.url?scp=34250802052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250802052&partnerID=8YFLogxK
U2 - 10.1097/01.tp.0000264056.20105.b4
DO - 10.1097/01.tp.0000264056.20105.b4
M3 - Article
C2 - 17589351
AN - SCOPUS:34250802052
SN - 0041-1337
VL - 83
SP - 1648
EP - 1651
JO - Transplantation
JF - Transplantation
IS - 12
ER -